Zenas BioPharma (NASDAQ:ZBIO) announced its full-year 2025 financial results on March 16, 2026, marking a pivotal year that has positioned the Waltham, Massachusetts-based biotech for its first potential product launch.
Olema Oncology (NASDAQ:OLMA) announced its fourth-quarter and full-year 2025 financial results on Monday, highlighting a year of substantial capital formation and clinical acceleration.
Relay Therapeutics (NASDAQ:RLAY) announced clinical data from its Phase 1/2 ReDiscover trial on Monday, providing a significant update on the efficacy and safety of zovegalisib (formerly RLY-2608).
Canopy Growth (NASDAQ:CGC) and MTL Cannabis announced the successful closing of their previously disclosed arrangement on Monday.
Annovis Bio (NYSE:ANVS) reported its full-year 2025 financial results and clinical milestones on March 16, 2026, highlighting a period of aggressive execution for its neurodegenerative disease pipeline.
Nasus Pharma (NYSE:NSRX) announced positive topline results from its Phase 2 clinical study of NS002, a proprietary intranasal epinephrine powder designed to treat life-threatening allergic reactions.
Agenus (NASDAQ:AGEN) reported its financial results for the fourth quarter and full year ended December 31, 2025, marking a transition from a purely clinical-stage company to one generating initial pre-commercial revenue.
CytomX Therapeutics (NASDAQ:CTMX) reported its full-year 2025 financial results and a strategic business update on March 16, 2026, highlighting the continued evolution of its Probody® platform.
WW International (NASDAQ:WW) reported its fourth-quarter and full-year 2025 results on March 16, 2026, signaling a successful stabilization of its business model following a major financial restructuring mid-year.
Eli Lilly and Company (NYSE:LLY) on Monday announced positive topline results from the Phase 3 ADorable-1 trial evaluating EBGLYSS (lebrikizumab-lbkz) in patients aged six months to 18 years with moderate-to-severe atopic dermatitis.
Alto Neuroscience (NYSE:ANRO) reported its full-year 2025 financial results, highlighting a strengthened balance sheet and a disciplined approach to research and development.
Immutep (NASDAQ:IMMP) announced on March 13, 2026, that it will shut down its Phase III TACTI-004 clinical trial evaluating eftilagimod alpha ("efti") in combination with anti-PD-1 therapy for first-line non-small cell lung cancer (NSCLC).
